Bayer AG's Stivarga Approved for Further Indication in Japan

Published: Aug 21, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Germany's largest drugmaker Bayer said it received regulatory approval in Japan for the marketing of cancer treatment Stivarga for patients with gastrointestinal stromal tumours who have progressed after prior systemic cancer therapy. Stivarga is already approved in several countries, including the United States and Japan, for the treatment of patients with metastatic colorectal cancer (mCRC), Bayer said on Tuesday.

Help employers find you! Check out all the jobs and post your resume.

Back to news